Skip to main content

Table 3 Relationships between clinicopathological characteristics and PD-L1 expression in tumor-infiltrating immune cells

From: PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population

Clinicopathological characteristics

Overall

PD-L1 (+)

PD-L1 (−)

Odds ratio (95% CI)

Global P

 

378

152(40.2%)

226(59.8%)

  

Age at diagnosis

   

0.853(0.565–1.288)

0.450

  ≥ 60 years

188

72(38.3%)

116(61.7%)

  

  < 60 years

190

80(42.1%)

110(57.9%)

  

Gender

   

1.205(0.707–2.055)

0.494

 Male

307

126(41.0%)

181(59.0%)

  

 Female

71

26(36.6%)

45(63.4%)

  

Tumor differentiation

 Well

85

32(37.6%)

53(62.4%)

1

 

 Moderate

190

77(40.5%)

113(59.5%)

1.129(0.667–1.909)

0.652

 Poor

91

37(40.7%)

54(59.3%)

1.135(0.619–2.081)

0.683

 Basaloid

12

6(50.0%)

6(50.0%)

1.656(0.492–5.575)

0.415

Location

 Upper thoracic

61

24(39.3%)

37(60.7%)

1

 

 Middle thoracic

209

71(34.0%)

138(66.0%)

0.793(0.441–1.428)

0.440

 Lower thoracic

108

57(52.8%)

51(47.2%)

1.723(0.911–3.260)

0.094

PT status

   

1.211(0.760–1.931)

0.421

 pT2

103

38(36.9%)

65(63.1%)

  

 pT3-4a

275

114(41.5%)

161(58.5%)

  

PN status

   

1.630(1.286–2.067)

< 0.001

 pN0

189

53(28.0%)

136(72.0%)

  

 pN1

116

61(52.6%)

55(47.4%)

  

 pN2

52

26(50.0%)

26(50.0%)

  

 pN3

21

12(57.1%)

9(42.9%)

  

Vascular invasion

   

0.729(0.479–1.110)

0.141

 No

219

95(43.4%)

124(56.6%)

  

 Yes

159

57(35.8%)

102(64.2%)

  

Perineural invasion

   

0.939(0.606–1.455)

0.778

 No

253

103(40.7%)

150(59.3%)

  

 Yes

125

49(39.2%)

76(60.8%)

  

Metachronous hematogenous metastasis

   

0.989(0.574–1.707)

0.969

 No

313

126(40.3%)

187(59.7%)

  

 Yes

65

26(40.0%)

39(60.0%)